Glycilock Trio Forte 2 Tablet SR is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 2 mg, Metformin 1000 mg, and Voglibose 0.2 mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, promoting better glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, resulting in reduced postprandial hyperglycemia. The sustained-release (SR) formulation ensures a gradual release of active ingredients, optimizing therapeutic efficacy while minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Glycilock Trio Forte 2 is indicated for patients inadequately controlled on monotherapy or dual therapy and requires close monitoring of blood glucose levels and renal function during treatment. It should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular medical supervision. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rare allergic reactions.